The CEO and Chairman of the Board of Oasmia buys subscription rights in the ongoing rights issue

NEXT STORY
ARCS Foundation welcomes Mary Jo Whitehouse as Northern California Chapter Co-President
PREV STORY
OSE Immunotherapeutics and HalioDx Collaborate to Perform Immune Biomarker Exploratory Work during Atalante 1 Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

author_avatar
NASDAQ Market News

Context Therapeutics® Announces Closing of Initial Public Offering, Including Full Exercise of Underwriter’s Over-allotment Option

author_avatar
NASDAQ Market News

Genmab Announces Data to be Presented at 2018 ASH Annual Meeting

Media Release Thirty-five total abstracts on Genmab owned and partnered programs scheduled for presentation ...

author_avatar
NASDAQ Market News